{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T22:34:01Z","timestamp":1761863641921,"version":"build-2065373602"},"reference-count":30,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","primary-care-diabetes.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Primary Care Diabetes"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1016\/j.pcd.2016.12.001","type":"journal-article","created":{"date-parts":[[2016,12,23]],"date-time":"2016-12-23T01:18:39Z","timestamp":1482455919000},"page":"226-232","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Clinical correlates of persistently elevated liver enzymes in type 2 diabetic outpatients"],"prefix":"10.1016","volume":"11","author":[{"given":"Annalisa","family":"Giandalia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabetta Lucia","family":"Romeo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Concetta","family":"Ruffo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Muscianisi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Letterio","family":"Giorgianni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fiorella","family":"Forte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Domenico","family":"Cucinotta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppina Tiziana","family":"Russo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pcd.2016.12.001_bib0005","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1053\/gast.2002.34168","article-title":"Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma","volume":"123","author":"Bugianesi","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.pcd.2016.12.001_bib0010","doi-asserted-by":"crossref","first-page":"S99","DOI":"10.1002\/hep.20973","article-title":"Nonalcoholic fatty liver disease: from steatosis to cirrhosis","volume":"43","author":"Farrell","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.pcd.2016.12.001_bib0015","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1097\/01.mol.0000174153.53683.f2","article-title":"Nonalcoholic fatty liver disease and the metabolic syndrome","volume":"16","author":"Marchesini","year":"2005","journal-title":"Curr. Opin. Lipidol."},{"key":"10.1016\/j.pcd.2016.12.001_bib0020","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1080\/07853890510011445","article-title":"Is liver disease a threat to patients with metabolic disorders?","volume":"37","author":"Marchesini","year":"2005","journal-title":"Ann. Med."},{"key":"10.1016\/j.pcd.2016.12.001_bib0025","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/S1542-3565(04)00014-X","article-title":"Nonalcoholoc fatty liver disease in patients with type 2 diabetes","volume":"2","author":"Yanoussi","year":"2004","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.pcd.2016.12.001_bib0030","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.dld.2008.02.003","article-title":"University of Naples Federico II: italy. Consensus recommendations for managing asymptomatic persistent non-virus non-alcohol related elevation of aminotransferase levels: suggestions for diagnostic procedures and monitoring","volume":"40","author":"Morisco","year":"2008","journal-title":"Dig. Liver Dis."},{"key":"10.1016\/j.pcd.2016.12.001_bib0035","first-page":"1003","article-title":"Causes and evaluation of mildly elevated liver transaminase levels","volume":"84","author":"Oh","year":"2011","journal-title":"Am. Fam. Physician"},{"key":"10.1016\/j.pcd.2016.12.001_bib0040","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.2337\/diabetes.51.6.1889","article-title":"High alanine aminotransferase is associated with decreased hepatic insulin sensitivity and predicts the development of type 2 diabetes","volume":"51","author":"Vozarova","year":"2002","journal-title":"Diabetes"},{"key":"10.1016\/j.pcd.2016.12.001_bib0045","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.2337\/diacare.27.6.1427","article-title":"Serum gamma-glutamyltransferase and risk of metabolic syndrome and type 2 diabetes in middle-aged Japanese men","volume":"27","author":"Nakanishi","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.pcd.2016.12.001_bib0050","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.2337\/diacare.28.12.2913","article-title":"Hepatic enzymes the metabolic syndrome, and the risk of type 2 diabetes in older men","volume":"28","author":"Wannamethee","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1016\/j.pcd.2016.12.001_bib0055","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1002\/dmrr.666","article-title":"Alanine aminotransferase as a marker of nonalcoholic fatty liver disease in relation to type 2 diabetes mellitus and cardiovascular disease","volume":"22","author":"Schindhelm","year":"2006","journal-title":"Diabetes Metab. Res. Rev."},{"key":"10.1016\/j.pcd.2016.12.001_bib0060","doi-asserted-by":"crossref","first-page":"3541","DOI":"10.2337\/diabetes.54.12.3541","article-title":"Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients","volume":"54","author":"Targher","year":"2005","journal-title":"Diabetes"},{"key":"10.1016\/j.pcd.2016.12.001_bib0065","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/dmrr.744","article-title":"Prognostic value of serum liver enzymes levels in type 2 diabetic patients","volume":"23","author":"Monami","year":"2007","journal-title":"Diabetes Metab. Res. Rev."},{"key":"10.1016\/j.pcd.2016.12.001_bib0070","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/S2213-8587(14)70032-4","article-title":"Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome","volume":"2","author":"Yki-Jarvinen","year":"2014","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.pcd.2016.12.001_bib0075","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","article-title":"EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease","volume":"64","author":"European Association for the Study of the Liver (EASL)","year":"2016","journal-title":"J. Hepatol."},{"issue":"Suppl. 1","key":"10.1016\/j.pcd.2016.12.001_bib0080","first-page":"S41","article-title":"Standards of medical care in diabetes 2015","volume":"38","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.pcd.2016.12.001_bib0085","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1093\/clinchem\/18.6.499","article-title":"Estimation of the concentration of low density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge","volume":"18","author":"Friedewald","year":"1972","journal-title":"Clin. Chem."},{"key":"10.1016\/j.pcd.2016.12.001_bib0090","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1053\/gast.2003.50032","article-title":"Defining nonalcoholic fatty liver disease: implications for epidemiologic studies","volume":"124","author":"Clark","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.pcd.2016.12.001_bib0095","doi-asserted-by":"crossref","first-page":"348","DOI":"10.7326\/0003-4819-148-5-200803040-00005","article-title":"Brief communication: clinical implications of short-term variability in liver function test results","volume":"148","author":"Lazo","year":"2008","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.pcd.2016.12.001_bib0100","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1210\/jc.2015-1966","article-title":"Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus and normal plasma aminotransferase levels","volume":"100","author":"Portillo-Sanchez","year":"2015","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.pcd.2016.12.001_bib0105","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1053\/j.gastro.2008.01.037","article-title":"Parental obesity and offspring serum alanine and aspartate aminotransferase levels: the Framingham heart study","volume":"134","author":"Loomba","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.pcd.2016.12.001_bib0110","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s00592-011-0261-5","article-title":"Transaminase levels in the upper normal range are associated with oral hypoglycemic drug therapy failure in patients with type 2 diabetes","volume":"49","author":"Irace","year":"2012","journal-title":"Acta Diabetol."},{"key":"10.1016\/j.pcd.2016.12.001_bib0115","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1001\/jama.285.19.2486","article-title":"Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III)","volume":"285","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.pcd.2016.12.001_bib0120","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1111\/j.1440-1746.2010.06253.x","article-title":"A fresh look at NASH pathogenesis. Part 1: the metabolic movers","volume":"25","author":"Larter","year":"2010","journal-title":"J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.pcd.2016.12.001_bib0125","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.3390\/nu5051544","article-title":"Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease","volume":"5","author":"Gaggini","year":"2013","journal-title":"Nutrients"},{"key":"10.1016\/j.pcd.2016.12.001_bib0130","doi-asserted-by":"crossref","first-page":"632","DOI":"10.2337\/dc15-1876","article-title":"Metabolic Impact of Nonalcoholic Steatohepatitis in Obese Patients With Type 2 Diabetes","volume":"39","author":"Lomonaco","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.pcd.2016.12.001_bib0135","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.2337\/diacare.22.12.2067","article-title":"Frequency of liver disease in type 2 diabetic patients treated with oral antidiabetic agents","volume":"22","author":"Jick","year":"1999","journal-title":"Diabetes Care"},{"key":"10.1016\/j.pcd.2016.12.001_bib0140","doi-asserted-by":"crossref","first-page":"349","DOI":"10.4065\/mcp.2009.0365","article-title":"Statins in the treatment of dyslipidemia in the presence of elevated liver aminotransferase levels: a therapeutic dilemma","volume":"85","author":"Calderon","year":"2010","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.pcd.2016.12.001_bib0145","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1592\/phco.28.4.522","article-title":"Safety of statin therapy in patients with preexisting liver disease","volume":"28","author":"Onofrei","year":"2008","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.pcd.2016.12.001_bib0150","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1002\/hep.22429","article-title":"Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes","volume":"48","author":"Fracanzani","year":"2008","journal-title":"Hepatology"}],"container-title":["Primary Care Diabetes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1751991816301309?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1751991816301309?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T23:56:16Z","timestamp":1761695776000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1751991816301309"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["S1751991816301309"],"URL":"https:\/\/doi.org\/10.1016\/j.pcd.2016.12.001","relation":{},"ISSN":["1751-9918"],"issn-type":[{"type":"print","value":"1751-9918"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical correlates of persistently elevated liver enzymes in type 2 diabetic outpatients","name":"articletitle","label":"Article Title"},{"value":"Primary Care Diabetes","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pcd.2016.12.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Primary Care Diabetes Europe. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}